Key Milestones in Lyme Disease and Tick-Borne Diagnosis
SANTA CLARA, CA / ACCESSWIRE / March 29, 2024 / Vibrant Wellness, a leader in specialty diagnostics and personalized health tools, today announced that its tick-borne test has received approval from the Wadsworth Center, part of the New York State Department of Health.
This approval will allow Vibrant to offer Lyme disease testing in New York, specifically testing for Borrelia burgdorferi IgG/IgM in serum samples and dried blood spots. This accomplishment highlights the Institute’s commitment to excellence, evidenced by CAP accreditation and additional New York State approvals in chemistry, hematology, and immunology.
Immunochip technology establishes new standard for Lyme disease diagnosis
Vibrant’s Lyme immunochip technology is a breakthrough in serological testing. Designed to exceed the limitations of traditional methods, it provides unparalleled sensitivity and specificity in the detection of Lyme disease. Lyme disease is a condition primarily caused by the North American bacterium Borrelia burgdorferi. By utilizing advanced high-density multiplexed protein microarrays, Vibrant’s test detects low levels of antibodies through an automated system with remarkable accuracy.
The Vibrant tick-borne disease test provides comprehensive assessment of 16 serological markers associated with Lyme disease to improve diagnostic accuracy. These markers include:
- Borrelia burgdorferi VlsE1
- Borrelia burgdorferi C6 peptide
- A wide range of peptides and proteins reflecting different Borrelia burgdorferi antigens
Immunochip and conventional methods
Vibrant’s immunochip technology represents a major advance in infectious disease diagnosis. Unlike traditional his ELISA and Western blot-based testing methods, this innovative platform can detect multiple pathogens simultaneously, reducing time to diagnosis and the burden of multiple tests. It is designed to improve the accuracy of Lyme disease and co-infection detection and provide a more complete picture of a patient’s health status.
Clinical impact and benefits
“New York State approval strengthens our commitment to patient care and accurate diagnosis by making our high-precision diagnostic technology available to healthcare professionals and patients across the state,” said Vibrant Wellness. CEO Vasanth Jayaraman said. “Our immunochip technology provides clinicians with an important tool to more effectively detect Lyme disease and co-infections, which is especially important in New York state, which is hit hard by these diseases. ”
This approval follows a rigorous evaluation in which the technology demonstrated excellent sensitivity and specificity. This is evidence that Vibrant’s Lyme and Co-Infections’ immunochip technology has the potential to impact positive patient outcomes and improve the standard of care in the diagnosis of tick-borne diseases.
About Vibrant Wellness: Vibrant Wellness is a leading biotechnology company located in Santa Clara, California. As a CLIA-certified laboratory, Vibrant offers life-changing clinical tests that enable healthcare providers to identify the root cause of their patients’ health problems. A leader in modern medicine and research, Vibrant uses cutting-edge, high-quality technology to deliver personalized health analytics. The company strongly believes that through personalized solutions based on comprehensive testing, everyone can achieve better health and a longer, more vibrant life. For more information, visit vivid-wellness.com.
The Vibrant Wellness test is developed by Vibrant America LLC, a CLIA-certified and CAP-certified laboratory. CLIA#:05D2078809. The test has not been cleared or approved by the U.S. Food and Drug Administration.
contact address
Tyana Smith
content manager
[email protected]
sauce: vibrant wellness
View the original press release on newswire.com.
